Jul 24, 2024, 01:00
Yige Bao: Our data from the high-risk UTUC nephron-sparing trial has been accepted at ESMO 2024
Yige Bao, Oncological Urologist and Microbiome researcher in West China Hospital, shared a post on X:
“Exciting news! Our data from the high-risk UTUC nephron-sparing trial has been accepted at ESMO 2024 (European Society for Medical Oncology Congress 2024)! Demonstrating the potential to preserve kidneys in carefully selected high-risk UTUC patients.”
Source: Yige Bao/X
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 5, 2025, 19:11
Aug 5, 2025, 18:55
Aug 5, 2025, 18:30
Aug 5, 2025, 18:18
Aug 5, 2025, 18:04
Aug 5, 2025, 17:52
Aug 5, 2025, 16:29
Aug 5, 2025, 16:07